Physician profile
Ritu Saini
NPI 1477763977
$4,653.03
in general payments reported to CMS, 2019-2025
29 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $479 · 2021: $750 · 2022: $688 · 2023: $795 · 2024: $513 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.45 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.81 | 2019-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $528.73 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $455.50 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $410.42 | 2020-2025 | |
| Lilly USA, LLC | $362.46 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $360.67 | 2022-2025 | Tremfya, Xarelto, Simponi Aria |
| Amgen INC. | $359.51 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $192.33 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $172.50 | 2019-2025 | Dupixent |
| Incyte Corporation | $137.11 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $136.80 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.11 | 2019-2021 | |
| Pfizer INC. | $113.26 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $96.33 | 2023-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $71.91 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $53.87 | 2019 | |
| Paratek Pharmaceuticals, INC. | $41.63 | 2022-2023 | Nuzyra |
| Mayne Pharma Commercial LLC | $41.57 | 2022 | |
| Journey Medical Corporation | $40.37 | 2020-2025 | |
| Genentech USA, INC. | $36.16 | 2019 | |
| Merck Sharp & Dohme LLC | $34.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.94 | 2023 | Cyltezo |
| Cipher Pharmaceuticals US LLC | $27.24 | 2025 | Natroba, Spinosad |
| Acelrx Pharmaceuticals, INC. | $22.43 | 2021 | |
| Organogenesis INC. | $22.36 | 2021 | |
| Prugen, INC. Pharmaceuticals | $20.15 | 2019 | |
| Almirall LLC | $19.51 | 2020 | |
| Celgene Corporation | $15.66 | 2019 | |
| Allergan, INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.